[Business Wire] Zoetis Inc (NYSE:ZTS)(TREND ANALYSIS) will participate in the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, in Las Vegas, Nev. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 6:00 p.m. EDT.
Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
The company is expected to announce next quarter earnings on May 05, at consensus estimate of $0.37. Zoetis Inc (ZTS) reported last quarter earnings on February 11. The Medical Drugs company announced earnings per share of $0.4 against a consensus Street estimate of $0.36, beating the average estimate by $0.04. This corresponds to a flat EPS compared to the same quarter of the previous fiscal year.
Zoetis Inc (NYSE:ZTS) is currently trading 1.84% below its 52-week-high, 64.88% above its 52-week-low. The 12-months range for the stock is $28.53 – $47.92. Zoetis Inc (ZTS) has a price to earnings ratio of 40.55 versus S&P 500 average of 17.42. ZTS stock price has outperformed the S&P 500 by 8.1%. The Medical Drugs company is currently valued at $23.56 billion and its share price closed the last trading session at $47.04. The stock has a 50-day moving average of $46.63 and a 200-day moving average of $43.07.
Zoetis Inc (ZTS) current short interest stands at 3.28 million shares. It has decreased by 17% from the same period of last month. Around 1% of the company’s shares, which are float, are short sold. With a 10-days average volume of 2.29 million shares, the number of days required to cover the short positions stand at 1.5 days.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently eighteen analysts that cover ZTS stock. Of those eighteen, nine have a Buy rating, eight have a Hold rating and one has a Sell rating. On a consensus basis this yields to an Overweight rating. The consensus target price stands at $48.31.
A recent analyst activity consisted of Gabelli& Co reiterating their Buy stance on November 26. Gabelli& Co increased their price target on ZTS from $44 to $53. This corresponds to a 12.67% upside from the last closing price. On the date of report, the stock closed at $44.51.
Argus reiterated their Buy stance, and increased their price target on ZTS from $38 to $41. This corresponds to a 12.84% downside from the last closing price. On the date of report, the stock closed at $36.04.
Zoetis Inc discovers, develops, manufactures and commercializes animal health medicines and vaccines, with a focus on both livestock and companion animals. The Companies products are sold in North America, Europe, Africa, Asia, Australia and Latin America.